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Abstract
Background With more patients qualifying for heart
transplantation (HT) and fewer hearts being trans-
planted, it is vital to look for other options. To date,
only organs from brain-dead donors have been used
for HT in the Netherlands. We investigated waiting
list mortality in all Dutch HT centres and the poten-
tial of donation after circulatory death (DCD) HT in
the Netherlands.
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Methods Two different cohorts were evaluated. One
cohort was defined as patients who were newly listed
or were already on the waiting list for HT between
January 2013 and December 2017. Follow-up contin-
ued until September 2018 and waiting list mortality
was calculated. A second cohort of all DCD donors
in the Netherlands (lung, liver, kidney and pancreas)
between January 2013 and December 2017 was used
to calculate the potential of DCD HT.
Results Out of 395 patients on the waiting list for HT,
196 (50%) received transplants after a median waiting
time of 2.6 years. In total, 15% died while on the wait-
ing list before a suitable donor heart became available.
We identified 1006 DCD donors. After applying exclu-
sion criteria and an age limit of 50 years, 122 potential
heart donors remained. This number increased to 220
when the age limit was extended to 57 years.
Conclusion Waiting list mortality in the Netherlands
is high. HT using organs from DCD donors has great
potential in the Netherlands and could lead to a re-
duction in waiting list mortality. Cardiac screening
will eventually determine the true potential.
What’s new?
 One out of seven adult patients and one out of
four paediatric patients die while on the waiting
list before a donor heart becomes available.
 Every second patient was not transplanted while
on the waiting list between 2013 and 2017.
 Donation after circulatory death (DCD) heart
transplantation (HT) has great potential to in-
crease the number of heart transplants per-
formed in the Netherlands.
 Cardiac screening in DCD donors is essential for
the success of a Dutch DCD HT programme.
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Introduction
The shortage of suitable donor hearts worldwide has
led to changes in the accepted donor pool. While the
average donor age was 29 years before 2000, this has
now increased to 43 and is still rising [1]. Besides
the use of older donor hearts, the complexity of the
patients on the waiting list has also increased, with
many more patients receiving mechanical circulatory
support; waiting times have also increased. Never-
theless, the 10-year cumulative survival has signifi-
cantly improved from between 53 and 65% for pa-
tients receiving transplants before 2000 to between
68 and 76% since 2000 [1–3]. However, the number
of patients on the waiting list has risen due to the
introduction of left ventricular assist devices (LVADs)
[4]. Up to now, only hearts donated after brain death
(DBD) have been used for heart transplantation (HT)
in the Netherlands. Since the successful introduc-
tion of machine perfusion, interest in the transplan-
tation of hearts donated after circulatory death (DCD)
has increased significantly [5]. In 2017, the Papworth
group reported an increase of almost 30% in the num-
ber of transplants since the introduction of the DCD
procedure [6]. Recently, similar findings were demon-
strated in Australia, showing an increase of almost
22% [7]. In the Netherlands, DCD transplantations are
already commonly performed for liver, lung, kidney
and pancreas with good results and represent around
50% of all transplant procedures [8]. Despite this ad-
vantage, the question remains what the potential is
for DCD HT in the Netherlands and what the impact
could be on waiting list mortality as well as on time
on the waiting list.
In this study we investigated the waiting list mor-
tality in all Dutch HT centres to illustrate the urgency
of implementing DCD HT, and studied the potential
of DCD HT in the Netherlands.
Methods
In order to calculate waiting list mortality, a cohort
was evaluated consisting of patients who were already
on the waiting list or were newly listed for HT in
the Netherlands between January 2013 and Decem-
ber 2017. Data were retrospectively collected by chart
review. For these patients, date of listing, date of heart
failure diagnosis and blood type were noted. Follow-
up was continued until September 2018. At the end
of the follow-up period, the status of the patient was
categorised into six groups: heart transplant, death
while on the waiting list, removed from the waiting
list due to improved cardiac condition, removed from
the waiting list due to deterioration of the condition,
removed from the waiting list due to a different rea-
son, and still listed.
Table 1 Inclusion and exclusion criteria used for eligibility
testing of donation after circulatory death (DCD) donors
Inclusion criteria Exclusion criteria
Maastricht classification III
or V DCD donor
Cardiac abnormalities
Age ≤57 years – History of cardiac surgery
Ejection fraction >50% (if
known)
– History of coronary abnormalities
No abnormalities on
echocardiography (if known)
– History of myocardial infarction
– History of congenital heart disease
Malignancies
– Malignancies in the past five years
– History of malignant melanoma
– Primary intracerebral lymphoma
– Secondary intracerebral malignancies
Infections
– Human immunodeficiency virus








Functional warm ischaemia time >30min
(if known)a
Other exclusion criteria as used in
donation after brain death
aFunctional warm ischaemia time starts when the systolic blood pressure
drops under 50mmHg and ends when cardioplegia is administered
A second cohort was used to calculate the poten-
tial of DCD HT in the Netherlands. This cohort was
obtained from the Dutch Transplant Society and con-
sisted of all donors who donated their organs for DCD
transplantation (lung, liver, kidney or pancreas) in
the Netherlands between January 2013 and December
2017. All of these patients were screened retrospec-
tively for contraindications for DCD HT. Contraindi-
cations were scored according to the Papworth list of
contraindications as published by Messer et al. [6]. In
addition to the inclusion criteria of Messer et al., both
DCD type III donors (controlled DCD, donors await-
ing cardiac arrest) and DCD type V donors (controlled
DCD, donation after euthanasia) were included [9], as
donation after euthanasia is allowed in the Nether-
lands [10]. All inclusion and exclusion criteria are
listed in Tab. 1. For the final analyses, two age limits
were used: a maximum donor age of 50 years (donor
age limit at the start of the DCD HT programme in
Papworth) and a maximum donor age of 57 years
(as is currently used by the English and Australian
groups following successful introduction of their DCD
HT programme).
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The study was performed in accordance with the
Declaration of Helsinki and the Medical Research In-
volving Human Subjects Act (non-WMO research).
Statistical analysis
Categorical variables are presented as an absolute
number with percentages (%). Continuous variables
are presented as mean± standard deviation when
normally distributed or as median with interquartile
range (IQR) when not normally distributed.
Continuous variables between groups were com-
pared with a Student t-test when normally distributed
or a Mann-Whitney test with non-normally dis-
tributed data. When more than two groups were
included, one-way ANOVA (normally distributed) or
Kruskal-Wallis test (not normally distributed) were
used.
For categorical variables the chi-square test was
used or Fisher’s exact test when appropriate.
Survival analysis and comparisons in the number
of HTs per blood type were performed with Kaplan-
Meier methods. Kaplan-Meier event curves were com-
pared using the log-rank test.
Statistical analyses were performed using SPSS,
version 25.0 (SPSS Inc., IBM, Chicago, IL, USA) and




Between January 2013 and December 2017, a total of
395 patients were on the HT waiting list. Their base-
line characteristics are summarised in Tab. 2. The me-
dian age at the time of listing was 50 years (IQR 40–58),
with 35 (9%) being under the age of 18. The minority
were female, 146 (37%) patients. Blood types O (48%)
and A (42%) were most common (Tab. 2). The me-
dian time between heart failure diagnosis and listing
Table 2 Baseline characteristics of patients on the







Age at listing 50 (40–58) 51 (43–59) 8 (2–13)
Female gender 146 (37) 123 (34) 23 (66)
Blood type
– A 164 (42) 154 (43) 10 (29)
– B 32 (8) 27 (8) 5 (14)
– AB 9 (2) 8 (2) 1 (3)
– O 190 (48) 171 (48) 19 (54)








Baseline characteristics with categorical variables are presented in absolute
numbers (percentages) and continuous variables with medians (IQR)
HF heart failure







Transplant 196 (50) 172 (48) 24 (69)
Died on waiting list 60 (15) 51 (14) 9 (26)
Removed from waiting list due to:
– Deteriorated condition 9 (2) 9 (3) 0 (0)
– Improved cardiac
function
11 (3) 11 (3) 0 (0)
– Other 8 (2) 7 (2) 1 (3)
Still on waiting list 111 (28) 110 (31) 1 (3)
Endpoints are given with categorical variables in absolute numbers (%)
was 5.2 (1.7–10.2) years. The median duration be-
tween heart failure diagnosis and listing was signifi-
cantly shorter in patients <18 years old compared with
adults (1.3 vs 5.8 years, respectively, p= 0.012).
At the end of follow-up, 196 (50%) patients had un-
dergone a HT and 28 (7%) were removed from the
waiting list (see Tab. 3). Nine (2%) were removed be-
cause of deterioration of the condition and 11 (3%)
because of improvement of their cardiac condition.
Eight (2%) were removed due to another reason. In
total, 60 (15%) patients died while on the waiting list
before a suitable donor heart became available. Nine
(26%) paediatric patients died versus 51 (14%) adult
patients (p= 0.069).
The median waiting time for patients until HT was
2.6 years (IQR 2.2–2.9). Patients listed under the age
of 18 who underwent a transplantation had a sig-
nificantly shorter median waiting time compared to
adults (0.5 years vs 2.8 years, respectively, p< 0.001).
Maximum time on the waiting list for a patient who
received a transplant was 6.9 years. Overall, the max-
imum time on the waiting list was 8.0 years. This
specific patient died while on the waiting list. Wait-
ing time for HT was significantly different between
blood types (median of 3.4 vs 2.4 vs 1.5 vs 1.4 years
for blood types O, A, B and AB, respectively, p<0.001;
see Fig. 1). The total percentage of patients who even-
tually underwent a transplantation during this period
also differed between blood types. Patients with blood
type AB received a transplant most often, followed by
blood types B, A and O (78% vs 59% vs 55% vs 42%,
respectively, p=0.01).
Potential for DCD heart transplantation
Between January 2013 and December 2017, 1006 DCD
procedures were performed in the Netherlands. The
average donor age was 53.4± 14.8 years; 319 were aged
≤50 and 551 were ≤57 years (Fig. 2).
Most donors (959, 95%) were DCD type III (con-
trolled DCD, donor awaiting cardiac arrest), 35 (4%)
were DCD type V (controlled DCD, donation after
euthanasia), 10 (1%) were DCD type II (uncontrolled
DCD, unsuccessful resuscitation) and 2 (0%) were
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Fig. 1 The number of patients receiving a heart transplant
(HT) since being added to the waiting list, stratified by blood
type
DCD type I (uncontrolled DCD, dead in the out-of-
hospital setting).
In Fig. 3, the potential for donors aged ≤50 or
≤57 years is displayed. When applying a maximum
donor age of 50 years and the exclusion criteria men-
tioned in Tab. 1, 122 donors could have been suitable
candidates for heart donation. When the maximum
donor age of 57 years was applied, this number in-
creased to 220 potential donor hearts. Hypothetically,
this would mean an increase of over 100% in com-
parison to the number of DBD transplants performed
between 2013 and 2017 (n=184). This would only be
the case if all of these donors had hearts suitable for
donation, died within the maximal functional warm
ischemia time (FWIT) and had matching recipients
listed. Furthermore, cardiac screening was performed
in only 1% of the cases.
The median age of the donors who were eligible
for DCD HT (≤50 years old) was 43 years (IQR 27–47)
When the age limit of donors was set at 57 years,
the median donor age was 49.5 years (IQR 40–54).
Twelve donors were under the age of 18, the youngest
being 7 years old. Three of these paediatric donors
had a body weight <25kg, which is the lowest weight
recorded for the successful use of machine perfusion
Fig. 2 Age distribution of donation after circulatory death
donors in the Netherlands between 2013 and 2017
Total DCD donors
n=1006
DCD donors aged ≤50
n=319




Potenally suitable DCD 
donors ≤50
n=122





Fig. 3 Potential for transplantation of hearts from donation
after circulatory death (DCD) donors aged under 50 or 57 years
in DCD HT to date (no reference given/anecdotal ev-
idence only).
Discussion
In this study, we found a substantial waiting list time
for HT, which was accompanied by a high waiting list
mortality in the Netherlands (15%). Furthermore, we
established great potential of DCD HT.
In the Netherlands, the number of HTs has re-
mained stable, but very low (~40/year) in the past few
years [8]. Yet, the number of patients on the waiting
list has greatly increased. As such, there is reason to
explore the potential of DCD donors. The present
study suggests that at least part of the donor heart
shortage could be alleviated by extending HT to DCD
donations. Of course, the actual potential depends on
cardiac screening of DCD donors as well as consent
for heart donation. In addition, the actual number of
DCD HTs will be dependent on several other factors.
For example, a potential donor must have a minimum
weight (and thus age), as at least 1 l of donor blood is
needed to prime the machine perfusion device that is
used during DCD HT [6, 7]. At present, no standard
cardiac screening (electrocardiography, echocardio-
graphy and coronary status) is performed in DCD
donors. Cardiac screening will determine how many
donors are eventually suitable to donate their heart
for DCD HT. It is anticipated that some hearts will
not be deemed suitable for HT because of coronary
artery disease and/or left ventricular dysfunction. Fi-
nally, the duration of FWIT is of importance. FWIT
starts when the systolic blood pressure drops below
50mmHg and ends when cardioplegia is administered
(with an upper limit of 30min), effectively stopping
ischaemia [6].
DCD heart transplantation in other countries
In several countries, the potential of DCDHT has been
calculated, varying between 4 and 17% in the USA and
Belgium and 56% in the UK [11–15]. Australia and
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the UK started DCD HT in 2014 and 2015, respec-
tively. Since the start of the DCD HT programmes,
both countries have seen a significant increase in HT
numbers of 22 and 33%, respectively [6, 7]. The po-
tential in the Netherlands could be even higher. DCD
donation is already accepted for the kidney, liver, lung
and pancreas, which could make the implementation
of DCD HT more accessible [8]. Furthermore, dona-
tion after euthanasia is possible in the Netherlands
[10], which could increase the number of heart donors
even more. We believe that DCD HT (compared to
other countries) could increase the number of HTs
by 10–15 annually, increasing the number of HTs by
26–40% over the coming years.
Using machine perfusion for DCD heart
transplantation
Cardiac screening before life support of the donor
is withdrawn in the intensive care unit is a must to
assess which hearts might meet the inclusion crite-
ria. Hearts from DCD donors can suffer from signifi-
cant ischaemic injury prior to organ procurement [16],
which is one of the factors leading to primary graft
dysfunction [17]. With the introduction of machine
perfusion in transplantation, it is possible to perfuse
a potential donor heart ex vivo until it is transplanted
in the recipient. Theoretically, this may reduce the
cardiac ischaemia/reperfusion injury [16]. One of the
disadvantages of DCD HT is that the cardiothoracic
surgeon cannot functionally assess the heart function
in a loaded condition. When the heart has been ex-
planted and is beating on the machine perfusion de-
vice, surrogate markers such as lactate are used to
assess the quality of the heart [6]. When lactate levels
rise during machine perfusion, the heart might be re-
jected for HT. When lactate levels show a downward
trend, the heart is deemed suitable for transplanta-
tion [5]. However, it is questionable whether lactate is
the ideal biomarker. The Australian group started with
a level of 5mmol/l for lactate as the threshold for DCD
HT. However, HT was also successfully performed in
patients with a lactate concentration >5mmol/l. This
is why the group decided to use a downward trend
instead of a threshold of 5mmol/l for lactate [7].
Alternative markers need to be explored in order to
obtain more solid evidence to decide whether a heart
is suitable for HT. Donor management, organ resus-
citation, preservation and evaluation are essential to
minimise the risk of primary graft dysfunction and
successful further application of DCD heart transplan-
tation in the future.
Waiting list mortality
Adult mortality is comparable with that in the UNOS
database (a US heart transplant database), 14% versus
16%, respectively [18]. It is agreed that all children
under the age of 16 are listed as International High
Table 4 ‘I NEED HELP’ acronym
I Inotropes Previous or ongoing requirement for





Persisting NYHA class III or IV and/or
persisting high BNP or NT-proBNP
E End-organ
dysfunction
Worsening renal or liver dysfunction in the
setting of heart failure
E Ejection fraction Very low ejection fraction <20%
D Defibrillation shocks Recurrent appropriate defibrillator shocks
H Hospitalisations More than 1 hospitalisation for heart failure
in the last 12 months
E Edema/Escalating
diuretics
Persisting fluid overload and/or increasing
diuretic requirement
L Low blood pressure Consistently low BP with a systolic
<90–100mmHg
P Prognostic medication Inability to up-titrate (or need to decrease or
cease) ACEI, β-blockers, ARNIs or MRAs
(Adapted from [20] with permission)
ACEI angiotensin-converting enzyme inhibitor, ARNI angiotensin-receptor
neprilysin inhibitor, BNP B-type natriuretic peptide, BP blood pressure,
MRA mineralocorticoid receptor antagonist, NT-proBNP N-terminal
pro-b-type natriuretic peptide, NYHA New York Heart Association
Urgent, while donors in the Eurotransplant zone are
prioritised for paediatric HT patients [19]. This status
is maintained until a child turns 16 years of age, after
which the child is put on the adult waiting list (except
when the skeletal age is still under the age of 16). DCD
HT could help reduce mortality.
Of course, timely referral for HT is essential. An
acronym to determine which patients should be re-
ferred to a tertiary centre for LVAD and/or HT evalu-
ation is ‘I NEED HELP’ (Tab. 4; [20]). LVADs can keep
patients alive and in good condition while on the wait-
ing list. Yet patients with severe right ventricular fail-
ure or congenital cardiac defects are rarely candidates
for LVAD implantation. Furthermore, complications
during LVAD therapy often become refractory in the
long term. As such, the donor pool needs to be ex-
panded to decrease waiting time. Whether DCD HT
will decrease waiting time will depend on several fac-
tors, including the actual number of donors screened
and deemed suitable for DCD HT as well as the evo-
lution of LVAD therapy over time.
Donor pool expansion
Up until this year, an opt-in system was used in the
Netherlands, where people have to actively register to
be a donor [21]. As of mid-2020 this has been changed
to an opt-out system, potentially increasing the avail-
able donor pool.
Although long-term results of DCD HT are not
known yet, mid-term (5-year) outcomes are at least
comparable to those of DBD donation [6, 7]. To de-
crease time on the waiting list as well as waiting list
mortality, we strongly believe that DCD HT should
be introduced in the Netherlands in all HT centres
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to expand the donor pool. We expect this to become
a reality in 2021.
In conclusion, mortality rates on the waiting list are
high in the Netherlands, in part due to a shortage of
donors. DCD HT has great potential in the Nether-
lands to decrease time on the waiting list for HT and
as such also to reduce waiting list mortality. Cardiac
screening of DCD donors will be essential to deter-
mine the true potential of DCDHT in the Netherlands.
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